Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 2 results.

- Speech
Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II
Duhoux, François[UCL] Jager, Agnes Dirix, Luc Huizing, Manon Jerusalem, Guy Vuylsteke, Peter[UCL] De Cuypere, Eveline Breiner, Doris Mueller, Christian[UCL] Brignone, Chrystelle Triebel, Frederic[UCL] (2017) Annual Meeting of the American Society of Clinical Oncology (ASCO) — Chicago, IL, USA
- Journal article
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group
Vergote, Ignace Debruyne, Philippe Kridelka, Frédéric Berteloot, Patric Amant, Frédéric Honhon, Brigitte Lybaert, Willem Leunen, Karin Geldhof, Kurt Verhoeven, Didier Forget, Frédéric Vuylsteke, Peter D'Hondt, Lionel[UCL] Huizing, Manon Van Den Bulck, Heidi Laenen, Annouschka (2015) Gynecologic Oncology — Vol. 138, no. 2, p. 278-284 (2015)